A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Abemaciclib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Giredestrant (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Letrozole (Primary) ; Olaparib (Primary) ; Paclitaxel (Primary) ; Palbociclib (Primary) ; Trastuzumab emtansine (Primary) ; Goserelin; Leuprorelin; Triptorelin
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms BOUQUET
- Sponsors Roche
- 15 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Dec 2023 This trial has been completed in Belgium, according to the European Clinical Trials Database record.
- 24 Oct 2023 Interim results (n=41) from the cobimetinib and atezolizumab + bevacizumab arms, presented at the 48th European Society for Medical Oncology Congress.